Should I buy Roivant Sciences (ROIV) stock or is it too late?

Roivant Sciences · Health Care · price $33

See the full Roivant Sciences (ROIV) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Guggenheim — 77% of its targets hit on this sector (53 calls tested). It aims for $46 (+38 %), call made on September 10, 2026, maturing on September 10, 2027 (34 d ago).

The 6 reliable analysts $49+47 %

The 1 other firm $40+20 %

How to read it: the 6 reliable firms are not filtered by optimism — 6 aim above the price, 0 below, hence their $49 median. “The 1 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Roivant Sciences

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
JP Morgan	100 %	+51.5 %	7	$20 -40%
HC Wainwright & Co.	81 %	+49.8 %	21	$47 +41%
Goldman Sachs	50 %	+43.6 %	6	$33 -1%
Cantor Fitzgerald	78 %	+21.8 %	9	$15 -55%
SVB Leerink	80 %	+74.6 %	5	—
Truist Securities	40 %	-7.0 %	5	—

In short — Should you invest in Roivant Sciences? Is it too late, still worth it? Analysts are overwhelmingly positive (86% buy, median target $49, i.e. +47%), and the most reliable on ROIV targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

86% of analysts rate it a buy (Buy consensus, 7 ratings) — a sign of market conviction.
Median price target $49, i.e. +47% from the current price ($33).
The most reliable firm on ROIV, Citigroup (100% hit rate, 4 scored calls), targets $46 (call made on August 10, 2026, maturing on August 10, 2027) (+38%) in its most recent call, and $25 (call made on October 29, 2025, maturing on October 29, 2026) (-25%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 7 ratings, 1 is neutral.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on ROIV

Median target $49 (+47%) · 7 ratings · Buy consensus

Strong Buy00%

Buy686%

Hold114%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Roivant Sciences now?

We won't decide for you. The facts: 86% of analysts rate it a buy, median target $49 (+47%), and Citigroup (most reliable on ROIV, 100%) targets $46. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Roivant Sciences?

Not according to analysts: the median target ($49) is still +47% above the current price ($33) (most reliable on ROIV: Citigroup, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Roivant Sciences still worth investing in?

It depends on the gap between the price ($33) and its estimated value: analysts target $49 on median (+47%), with 86% buys (most reliable on ROIV: Citigroup, 100%). Cross-check with their real reliability on ROIV and the cautions above. Information, not advice.

What's the main risk in buying ROIV?

The consensus is not unanimous: of 7 ratings, 1 is neutral.

→ Go deeper: the full Roivant Sciences profile (consensus, analyst reliability, price target, performance).